Introducing
JASCAYD®▼ (nerandomilast)
The first new treatment licensed for both PPF and IPF in 10 years, expanding treatment options for eligible patients1–3
Introducing
JASCAYD®▼ (nerandomilast)
The first new treatment licensed for both PPF and IPF in 10 years, expanding treatment options for eligible patients1–3
JASCAYD® is indicated for the treatment of adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).3
The first and only preferential PDE4B inhibitor for PPF and IPF1–3
* JASCAYD® is not recommended in patients with severe hepatic impairment.3
- +/- AF: Each arm included patients who were on a background AF therapy, or JASCAYD® alone (monotherapy)1,2
- In FIBRONEERTM-ILD, 44% were on background nintedanib2
- In FIBRONEERTM-IPF, 45% were on background nintedanib and 32% were on background pirfenidone1
‡ In the FIBRONEERTM-ILD trial, 1178 patients underwent randomisation but 2 patients did not receive trial regimen.2
§ Most cases of diarrhoea were grade 1 or 2 in Common Terminology Criteria for Adverse Events. Grade 1: increase of <4 stools per day; Grade 2: increase of 4–6 stools per day.6,7
* JASCAYD® is not recommended in patients with severe hepatic impairment.3
Adverse reactions associated with JASCAYD® 18 mg3
MedDRA System | MedDRA term | Frequency category |
|---|---|---|
Gastrointestinal disorders | Diarrhoea | Very common |
Nausea | Common | |
Metabolism and nutrition disorders | Decreased appetite | Common |
Investigations | Weight decreased | Very common |
Musculoskeletal and connective tissue disorders | Back pain | Common |
‖ Frequency categories: very common (≥1/10), common (≥1/100 – <1/10).
Please refer to the JASCAYD® Summary of Product Characteristics for further information.3
* JASCAYD® is not recommended in patients with severe hepatic impairment.